Garenoxacin mesylate is a Small Molecule owned by FUJIFILM Toyama Chemical, and is involved in 7 clinical trials, which were completed.
Garenoxacin mesylate is a topoisomerase IV, DNA gyrase inhibitor. It works by inhibiting bacterial DNA gyrase (main target in gram negative bacteria) and topoisomerase IV (main target in gram +ve bacteria). The major mechanism of action requires cell division quinolones also have other mechanisms of action which result in them being active against bacteria that are not actively replicating. The cross outer membrane of gram negative bacteria via porins affinity for bacterial target enzymes is 1000 times that for equivalent human enzymes minimum inhibitory concentration (MIC) is increased in the presence of magnesium and in acid environments (pH <6). It acts by inhibition of a metabolic pathway and disruption of bacterial membrane structure.
The revenue for Garenoxacin mesylate is expected to reach a total of $112m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Garenoxacin mesylate NPV Report.
Garenoxacin mesylate is originated and owned by FUJIFILM Toyama Chemical. Astellas Pharma and Taisho Pharmaceutical Holdings are the other companies associated in development or marketing of Garenoxacin mesylate.
Garenoxacin mesylate Overview
Garenoxacin mesylate (Geninax) is a quinolone derivative, acts as antibiotic or antibacterial agent. It is formulated as film-coated tablets for oral route of administration. It is indicated for the treatment of infections such as pharngitis, laryngitis, tonsillitis, acute bronchitis, pneumonia, chronic respiratory lesions secondary infection, otitis media and sinusitis caused by susceptible microrganisms.
Garenoxacin mesylate (Geninax, T-3811) was under development for the treatment of bacterial infections in Japan as injectable formulation, and in EU and US as oral and injectable formulations.
Taisho Pharmaceutical Holdings Overview
Taisho Pharmaceutical Holdings (Taisho Pharmaceutical) develops, manufactures and markets self-medication drugs and prescription pharmaceuticals. The company’s self-medication products comprise over the counter (OTC) products, quasi-drugs and health food products. Its prescription pharmaceuticals portfolio includes ethical drugs in the fields of infectious diseases, orthopedic disorders, central nervous system (CNS) diseases and metabolic diseases. Taisho Pharmaceutical provide its products under Pabron, Lipovitan D, Riup, Livita, Colac, Zosyn, Clarith, Edirol, Palux, Geninax, and Lorcam brand names. The company operates through its subsidiaries located in the Philippines, Indonesia, Malaysia, Thailand, Vietnam, China, Singapore, Taiwan and the US. Taisho Pharmaceutical is headquartered in Toshima-ku, Tokyo, Japan.
The company reported revenues of (Yen) JPY268,203 million for the fiscal year ended March 2022 (FY2022), a decrease of 4.9% over FY2021. In FY2022, the company’s operating margin was 3.7%, compared to an operating margin of 6.2% in FY2021. In FY2022, the company recorded a net margin of 4.9%, compared to a net margin of 4.7% in FY2021.
The company reported revenues of JPY75,449 million for the second quarter ended September 2022, an increase of 9.2% over the previous quarter.
Quick View – Garenoxacin mesylate
Report Segments |
|
Drug Name |
|
Administration Pathway |
|
Therapeutic Areas |
|
Key Companies |
|
Highest Development Stage |
|